Confirmed Speakers


Hildegard Büning
Professor, Institute of Experimental Hematology, Hannover Medical School
President, European Society for Gene and Cell Therapy

Robert Dean Synthego 150x150Robert Deans
Chief Scientific Officer, Synthego
Tittle: Engineering Biology for future medicines.
See biography

rayRay Deshais
Senior Vice President and Head of Discovery Research, Amgen
Topic: Multispecific Molecular Drugs: Riding the wave of transformative innovation
See biography

roskaBotond Roska
Director, Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Professor, Faculty of Medicine and Faculty of Natural Science, University of Basel
Topic: Restoring vision using optogenetic therapy
See biography

Invited Speakers
Molecular Cell Surgery Invited Speakers 

Kathy High
Professor Emerita, Perelman School of Medicine of the University of Pennsylvania
Co-founder and former Head of R&D, Spark Therapeutics

Ryan Gill
Scientific Director, Novo Nordisk Center for Biosustainability, Dansk Technical University
CEO, Artisan Biotechnology

Beyond evolution Invited Speakers  
Tim Lu
CEO, SentiBio
Associate Professor, MIT

Martin Pule
Senior Vice President and CSO, Autolous
Clinical Associate Professor, UCL -University College London

Challenges and Marvels of Bioprocess Intensification Invited Speakers  
Daniel Karst
Manufacturer Scientist, Biogen

Marcella Yu
Director Process Science Cell Culture, Boehringer Ingelheim

Adaptive Manufacturing: Eng quality into process Invited Speakers   
Gene Schaefer
Senior Fellow, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), USA

Laura Segatori
Associate Professor of Bioengineering, Chemical and Biomolecular Engineering, and BioSciences, RICE University, Texas

Data, Data, data: how to get it and how to use it Invited Speakers    
Cleo Kontoravdi
Professor of Biological Systems Engineering, Department of Chemical Engineering, Imperial College London, UK

Alessandro Butté
Lecturer and Senior Researcher at ETH Zurich
CEO of DataHow AG

Bio breakthroughts Invited Speakers     
Manny Otero
Senior Vice-President, Technical Operations, Turnstone Biologics, USA

Claudia Lobato da Silva
Associate Professor,  iBB-Institute for Bioengineering and Biosciences,Instituto Superior Técnico, Universidade de Lisboa, Portugal
Engineering Biology for Future Medicines 

Robert Dean Synthego 150x150Robert Deans, PhD

Dr Deans is CSO at Synthego, a genome engineering company automating a new era of cell and gene therapeutics. Prior to Synthego, Dr Deans was CTO at BlueRock Therapeutics, creating iPSC based allogeneic cell therapeutics by harnessing pluripotent stem cell biology and gene editing tools. Prior to BlueRock, Dr Deans was founding CSO at Rubius Therapeutics developing a platform of novel enucleated cell therapeutics based on genetic engineering and expansion of hematopoietic progenitors to mature red cells. Dr. Deans has more than 30 years of experience in adult stem cell therapeutics which includes HSC gene therapy and commercialization of progenitor cell therapeutics from bone marrow. Dr Deans was previously EVP at Athersys Inc, an adult stem cell therapeutics company now in late stage clinical development (MultiStem), and prior to that VP of Research at Osiris Inc, developing the Prochymal MSC based platform. Dr. Deans has been influential in stem cell and therapeutic societies in guiding translation and standardization of stem and progenitor cell practices

Multispecific Molecular Drugs: Riding the wave of transformative innovation

rayRaymond Deshaies, Ph.D., is senior vice president, Global Research

Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute. He has published over 150 papers on various subjects including discoveries of Sec61 translocon, cullin–RING ubiquitin ligases, and proteolysis-targeting chimeric molecules (Protacs).
In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Biosciences.
Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences, and American Academy of Arts and Sciences.

Restoring vision using optogenetic therapy

roskaDirector, Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Professor, Faculty of Medicine and Faculty of Natural Science, University of Basel

Botond Roska obtained his M.D. at the Semmelweis Medical School, a Ph.D. in neurobiology from the University of California, Berkeley and studied genetics and virology as a Harvard Society Fellow at Harvard University and the Harvard Medical School. He then led a research group at the Friedrich Miescher Institute in Basel from 2005-2018. In 2010 he became Professor at the Medical Faculty and in 2019 Professor at the Science Faculty of the University of Basel.
Since 2018 he is a founding director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB). At IOB he leads a research group focusing on the understanding of vision and its diseases and the development of gene therapies to restore vision. Botond Roska was elected as a member of the European Molecular Biology Organization (EMBO) in 2011 and the Academia Europaea in 2020. He has received several awards, including the Viva Award in 2010, the Alcon Award in 2011, the Alfred Vogt Award in 2013, the Cogan Award in 2016, the Bressler Prize and the W. Alden Spencer Award in 2018, the Louis-Jeantet Prize for Medicine, the Cloëtta Prize, the Semmelweis Budapest Award in 2019, the Körber European Science Prize and the Greenberg End Blindness Visionary Prize in 2020.

Technical Secretariat

logoGPBlanco Maria Cubi, 4 - Pral. | 08006 Barcelona (SPAIN)
Tel. +34 932.388.777 | Fax. +34 932.387.488
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.